Selenoprotein Gene Variants, Toenail Selenium Levels, and Risk for Advanced Prostate Cancer

M.S. Geybels*, P.A. van den Brandt, L.J. Schouten, F.J. van Schooten, S.G. van Breda, M.P. Rayman, F.R. Green, B.A.J. Verhage

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Lower selenium levels have been associated with increased risk of prostate cancer (PCa), and genetic variation in the selenoprotein genes selenoprotein P (SEPP1) and glutathione peroxidase 1 (GPX1) is thought to modify this relationship. We investigated whether the association between toenail selenium levels and advanced PCa risk in the prospective Netherlands Cohort Study is modified by common genetic variation in SEPP1 and GPX1. Toenail clippings were used to determine selenium levels and to isolate DNA for genotyping. This case-cohort study, which included 817 case subjects with advanced PCa and 1048 subcohort members, was analyzed with Cox regression models. All statistical tests were two-sided. Three genetic variants were associated with advanced (stage III/IV or IV) PCa risk: SEPP1 rs7579 (lower risk; P trend = .01), GPX1 rs17650792 (higher risk; P trend = .03), and GPX1 rs1800668 (lower risk; P trend = .005). Toenail selenium levels were inversely associated with advanced PCa risk, independently of common genetic variation in SEPP1 and GPX1.
Original languageEnglish
Article numberdju003
JournalJournal of the National Cancer Institute
Issue number3
Publication statusPublished - 1 Jan 2014

Cite this